Dataset Information


Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer.

ABSTRACT: High-grade Bladder Cancer (BLCA) represents the most aggressive and treatment-resistant cancer that renders the patients with poor survival. However, only a few biomarkers have been identified for the detection and treatment of BLCA. Recent studies show that ganglioside GD2 can be used as cancer biomarker and/or therapeutic target for various cancers. Despite its potential relevance in cancer diagnosis and therapeutics, the role of GD2 is unknown in BLCA. Here, we report for the first time that high-grade BLCA tissues and cell lines have higher expression of GD2 compared to low-grade by high-resolution Mass Spectrometry. The muscle invasive UMUC3 cell line showed high GD2, mesenchymal phenotype, and cell proliferation. Besides, we have shown the cancer stem cells (CSC) property (CD44hiCD24lo) of GD2+ UMUC3 and J82 cells. Also, the evaluation of lipid metabolism in GD2+ BLCA cell lines revealed higher levels of Phosphatidylinositol (PI), Phosphatidic acid (PA), Cardiolipin (CL) and lower levels of Phosphatidylserine (PS), plasmenyl-phosphatidylethanolamines (pPE), plasmenyl-phosphocholines (pPC), sphingomyelins (SM), triglycerides (TGs) and N-Acetylneuraminic acid. These findings are significantly correlated with the tissues of BLCA patients. Based on this evidence, we propose that GD2 may be used as an effective diagnostic and therapeutic target for aggressive BLCA.


PROVIDER: S-EPMC5707048 | BioStudies | 2017-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5173050 | BioStudies
2015-01-01 | S-EPMC4814363 | BioStudies
2019-01-01 | S-EPMC6582551 | BioStudies
1000-01-01 | S-EPMC6299383 | BioStudies
2017-01-01 | S-EPMC5244029 | BioStudies
2020-01-01 | S-EPMC7281198 | BioStudies
2013-01-01 | S-EPMC3743963 | BioStudies
2014-01-01 | S-EPMC4254523 | BioStudies
2012-04-12 | E-GEOD-36643 | ArrayExpress
2018-01-01 | S-EPMC6214371 | BioStudies